Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively ...

If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist.

People with irregular sleep schedules had a 26% higher risk of major cardiovascular events, even if they got the recommended ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist.

If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist. According to research ...

Losing the Odeon Theatre would effectively cut off access to one of the most affordable, accessible cultural experiences in ...

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

Broken heart syndrome” carries a significant risk of death and serious complications. Although the condition appears to be ...

CellProthera says it chose CELLforCURE by SEQENS as its CDMO for the quality of its infrastructure, equipment, and expertise of its team.

Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to ...